Drug
KCT-0809 ophthalmic solution
KCT-0809 ophthalmic solution is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_3
3
75%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 33 (75.0%)
Trials by Status
terminated125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_3
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT02503176
completedphase_3
A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT02503163
completedphase_3
A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT02503189
completedphase_2
A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01890941
Clinical Trials (4)
Showing 4 of 4 trials
NCT02503176Phase 3
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT02503163Phase 3
A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT02503189Phase 3
A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT01890941Phase 2
A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4